Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
Conditions: Endometrial Cancer; Papillary Serous; Clear Cell Endometrial Cancer Intervention: Radiation: Vaginal Cuff Brachytherapy Sponsor: University of Oklahoma Not yet recruiting - verified June 2017
CONCLUSIONS: VBT + CT was associated with superior survival outcomes in patients with early-stage serous carcinoma. For non-serous histology, treatment modality was not associated with a difference in survival, although patients with high-grade disease and no nodal dissection experienced benefit from EBRT. PMID: 31610885 [PubMed - as supplied by publisher]
This article reviews and interprets studies on adjuvant treatment of endometrial cancer published during the last 18 months. Recent findings For patients with intermediate and high intermediate risk endometrial cancer, vaginal brachytherapy remains the adjuvant therapy of choice. New molecular markers might help to define patients in this group for whom observation only is sufficient and women who might have benefitted from external beam radiotherapy. Preliminary results from large randomized controlled trials have shown that in early stage, high-risk endometrial cancer the addition of chemotherapy to external beam radi...
CONCLUSION: Among women with stage III uterine cancer, combination chemotherapy and external beam radiation is associated with decreased mortality compared with chemotherapy or radiation alone. PMID: 31188310 [PubMed - as supplied by publisher]
Publication date: Available online 10 May 2019Source: Gynecologic Oncology ReportsAuthor(s): Lindsey A. McAlarnen, Kelly Ryan, William Adams, Adam Gliniewicz, Abigail D. Winder, Margaret R. Liotta, Ronald K. Potkul, William Small, Matthew M. HarkenriderAbstractRegional recurrence of endometrial cancer is a challenging yet potentially curable group of patients without defined standard of care. Our aim is to determine optimal methods of salvage therapy for regionally recurrent endometrial cancer.Twenty-two cases of nodal, pelvic, or peritoneal cavity recurrences of endometrial cancer were identified from a single institution...
ConclusionsNeoadjuvant chemoradiation therapy effectively downstages the majority of locally advanced type II endometrial cancers, thereby increasing the likelihood of achieving complete resection with negative margins.
Conclusions: This retrospective study appears to show that adjuvant platinum-based chemotherapy plus VBT achieve very good results in endometrioid carcinoma. This combined treatment seems to be less effective in nonendometrioid carcinoma.Oncology
CONCLUSIONS: This retrospective study appears to show that adjuvant platinum-based chemotherapy plus VBT achieve very good results in endometrioid carcinoma. This combined treatment seems to be less effective in nonendometrioid carcinoma. PMID: 30904907 [PubMed - as supplied by publisher]
ConclusionsNeoadjuvant chemoradiotherapy effectively downstages the majority of locally-advanced type II endometrial cancers, thereby increasing the likelihood of achieving complete resection with negative margins.
Conclusions: The data suggest that HDR endovaginal brachytherapy, with or without chemotherapy, is very well tolerated with low rates of acute and late vaginal toxicities. Further prospective studies with higher numbers of patients and longer follow-up are necessary to evaluate acute and late toxicities after HDR endovaginal brachytherapy. PMID: 30662479 [PubMed]
This article will provide an opinion on adjuvant treatment of stage I–III endometrial cancer based on existing and evolving evidence. Recent findings For early-stage (I and II) intermediate risk endometrial cancer, vaginal brachytherapy reduces the risk of locoregional relapse. Recent studies have investigated the use of chemotherapy in early stage, high-risk patient population, but did not demonstrate a survival benefit. As such, chemotherapy is only recommended for selected patients at high risk for distant recurrence. On the other hand, for stage III disease, chemotherapy has a well established role. A landmark...